Novavax (NVAX) Total Non-Current Liabilities (2016 - 2025)
Novavax has reported Total Non-Current Liabilities over the past 16 years, most recently at $1.1 billion for Q4 2025.
- Quarterly results put Total Non-Current Liabilities at $1.1 billion for Q4 2025, down 41.62% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 41.62% YoY), and the annual figure for FY2025 was $1.1 billion, down 41.62%.
- Total Non-Current Liabilities for Q4 2025 was $1.1 billion at Novavax, down from $1.1 billion in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for NVAX hit a ceiling of $3.0 billion in Q2 2022 and a floor of $1.0 billion in Q2 2025.
- Median Total Non-Current Liabilities over the past 5 years was $2.0 billion (2021), compared with a mean of $2.1 billion.
- Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 351.93% in 2021 and later crashed 47.19% in 2025.
- Novavax's Total Non-Current Liabilities stood at $2.9 billion in 2021, then dropped by 1.71% to $2.8 billion in 2022, then decreased by 12.54% to $2.5 billion in 2023, then fell by 26.46% to $1.8 billion in 2024, then tumbled by 41.62% to $1.1 billion in 2025.
- The last three reported values for Total Non-Current Liabilities were $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.